- Home
- GDL vs DBVT Comparison
GDL vs DBVT Comparison
Compare GDL & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDL
- DBVT
- Stock Information
- Founded
- GDL 2006
- DBVT 2002
- Country
- GDL United States
- DBVT France
- Employees
- GDL N/A
- DBVT N/A
- Industry
- GDL Investment Managers
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GDL Finance
- DBVT Health Care
- Exchange
- GDL Nasdaq
- DBVT Nasdaq
- Market Cap
- GDL N/A
- DBVT 102.0M
- IPO Year
- GDL N/A
- DBVT N/A
- Fundamental
- Price
- GDL $8.25
- DBVT $6.46
- Analyst Decision
- GDL
- DBVT Strong Buy
- Analyst Count
- GDL 0
- DBVT 2
- Target Price
- GDL N/A
- DBVT $22.50
- AVG Volume (30 Days)
- GDL 11.2K
- DBVT 1.1M
- Earning Date
- GDL 01-01-0001
- DBVT 05-06-2025
- Dividend Yield
- GDL 6.02%
- DBVT N/A
- EPS Growth
- GDL N/A
- DBVT N/A
- EPS
- GDL N/A
- DBVT N/A
- Revenue
- GDL N/A
- DBVT $4,200,000.00
- Revenue This Year
- GDL N/A
- DBVT $1,679.52
- Revenue Next Year
- GDL N/A
- DBVT $535.67
- P/E Ratio
- GDL N/A
- DBVT N/A
- Revenue Growth
- GDL N/A
- DBVT N/A
- 52 Week Low
- GDL $7.65
- DBVT $0.44
- 52 Week High
- GDL $8.13
- DBVT $7.28
- Technical
- Relative Strength Index (RSI)
- GDL 45.88
- DBVT 65.77
- Support Level
- GDL $8.22
- DBVT $3.91
- Resistance Level
- GDL $8.31
- DBVT $7.28
- Average True Range (ATR)
- GDL 0.07
- DBVT 0.60
- MACD
- GDL -0.01
- DBVT 0.20
- Stochastic Oscillator
- GDL 18.75
- DBVT 75.67
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.